NYSE:CCChemours Stock Price, Forecast & News

Chemours' stock was trading at $10.66 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CC shares have increased by 52.1% and is now trading at $16.21. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemours in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Chemours.

Chemours is scheduled to release its next quarterly earnings announcement on Thursday, July 30th 2020. View our earnings forecast for Chemours.

Chemours will be holding an earnings conference call on Thursday, July 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Chemours Co (NYSE:CC) issued its earnings results on Tuesday, May, 5th. The specialty chemicals company reported $0.71 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.46 by $0.25. The specialty chemicals company earned $1.31 billion during the quarter, compared to the consensus estimate of $1.33 billion. Chemours had a negative net margin of 0.82% and a positive return on equity of 56.54%. The business's quarterly revenue was down 5.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.63 earnings per share. View Chemours' earnings history.

Chemours announced a quarterly dividend on Tuesday, April 28th. Shareholders of record on Friday, May 15th will be given a dividend of $0.25 per share on Monday, June 15th. This represents a $1.00 annualized dividend and a dividend yield of 6.17%. The ex-dividend date of this dividend is Thursday, May 14th. View Chemours' dividend history.

11 equities research analysts have issued 1 year price objectives for Chemours' stock. Their forecasts range from $8.00 to $21.00. On average, they anticipate Chemours' share price to reach $14.00 in the next twelve months. This suggests that the stock has a possible downside of 13.6%. View analysts' price targets for Chemours.

News stories about CC stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Chemours earned a news sentiment score of -1.5 on InfoTrie's scale. They also assigned news headlines about the specialty chemicals company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about Chemours.

Some companies that are related to Chemours include Johnson Matthey (JMPLY), Ashland Global (ASH), Huntsman (HUN), KURARAY CO LTD/ADR (KURRY), W. R. Grace & Co (GRA), SHOWA DENKO KK/ADR (SHWDY), Balchem (BCPC), Univar (UNVR), Ingevity (NGVT), Innospec (IOSP), Olin (OLN), PQ Group (PQG), GCP Applied Technologies (GCP), Livent (LTHM) and Hawkins (HWKN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemours investors own include E I Du Pont De Nemours And Co (DD), AT&T (T), NVIDIA (NVDA), Micron Technology (MU), Pfizer (PFE), Cisco Systems (CSCO), Intel (INTC), AbbVie (ABBV), Alibaba Group (BABA) and Energy Transfer LP Unit (ET).

Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."

Chemours' stock is owned by many different institutional and retail investors. Top institutional investors include DNB Asset Management AS (0.53%), Louisiana State Employees Retirement System (0.02%), Envestnet Asset Management Inc. (0.01%), Fruth Investment Management (0.01%) and Patriot Financial Group Insurance Agency LLC (0.00%). Company insiders that own Chemours stock include Amy Trojanowski, Bradley J Bell, David C Shelton, E Bryan Snell, Mark Newman, Mark P Vergnano, Mary B Cranston, Paul Kirsch, Richard H Brown and Susan M Kelliher. View institutional ownership trends for Chemours.

CC stock was sold by a variety of institutional investors in the last quarter, including DNB Asset Management AS, and Envestnet Asset Management Inc.. View insider buying and selling activity for Chemours.

CC stock was acquired by a variety of institutional investors in the last quarter, including Fruth Investment Management, Louisiana State Employees Retirement System, and Patriot Financial Group Insurance Agency LLC. Company insiders that have bought Chemours stock in the last two years include Bradley J Bell, David C Shelton, E Bryan Snell, Mark Newman, Mark P Vergnano, Mary B Cranston, Richard H Brown, and Susan M Kelliher. View insider buying and selling activity for Chemours.

Shares of CC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CC stock can currently be purchased for approximately $16.21.

Chemours has a market capitalization of $2.66 billion and generates $5.53 billion in revenue each year. The specialty chemicals company earns $-52,000,000.00 in net income (profit) each year or $2.51 on an earnings per share basis. Chemours employs 7,000 workers across the globe.

The official website for Chemours is www.chemours.com.

Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19801. The specialty chemicals company can be reached via phone at 302-773-1000 or via email at [email protected]